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Abstract
Background: Artesunate, an artemisinin-derived monomer, was reported to inhibit Cytomegalovirus (CMV) replication. We
aimed to compare the in-vitro anti-CMV activity of several artemisinin-derived monomers and newly synthesized artemisinin
dimers.
Methods: Four artemisinin monomers and two novel artemisinin-derived dimers were tested for anti-CMV activity in human
fibroblasts infected with luciferase-tagged highly–passaged laboratory adapted strain (Towne), and a clinical CMV isolate.
Compounds were evaluated for CMV inhibition and cytotoxicity.
Results: Artemisinin dimers effectively inhibited CMV replication in human foreskin fibroblasts and human embryonic lung
fibroblasts (EC50 for dimer sulfone carbamate and dimer primary alcohol 0.0660.00 mM and 0.1560.02 mM respectively, in
human foreskin fibroblasts) with no cytotxicity at concentrations required for complete CMV inhibition. All four artemisinin
monomers (artemisinin, artesunate, artemether and artefanilide) shared a similar degree of CMV inhibition amongst
themselves (in mM concentrations) which was significantly less than the inhibition achieved with artemisinin dimers
(P,0.0001). Similar to monomers, inhibition of CMV with artemisinin dimers appeared early in the virus life cycle as reflected
by decreased expression of the immediate early (IE1) protein.
Conclusions: Artemisinin dimers are potent and non-cytotoxic inhibitors of CMV replication. These compounds should be
studied as potential therapeutic agents for the treatment of CMV infection in humans.
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Introduction
Infection with CMV is common in humans, and is usually
asymptomatic [1,2]. In immunocompromised hosts such as
transplant recipients and patients with AIDS, CMV infection is
associated with significant morbidity and mortality [3,4]. It is also
the most common congenitally-acquired infection and the leading
infectious agent causing mental retardation and deafness in
congenitally infected children [5]. In recent years CMV has been
associated with a variety of syndromes including hypertension,
severe pulmonary complications in patients in intensive care-units,
and with a specific brain tumor, glioblastoma multiforme [6–9].
Although the exact role of CMV in these syndromes is unclear,
CMV replication appears to affect the natural history and
outcome of disease processes in immunocompetent individuals as
well. Thus, it is important and necessary to develop preventive and
treatment modalities for CMV. Despite significant ongoing
research effort, there is still no CMV vaccine approved for
universal or targeted use.
Available anti-CMV drugs, ganciclovir (GCV), cidofovir and
foscarnet, effectively inhibit virus replication by targeting the viral
DNA polymerase [10–12]. However, use of these drugs is
associated with considerable side effects such as bone marrow
toxicity (GCV) and nephrotoxicity (foscarnet and cidofovir)
[13,14]. Oral valganciclovir has good bioavailability and is used
in bone marrow and organ transplant recipients for CMV
prophylaxis and treatment. Valganciclovir has not been approved
yet for the treatment of infants with congenital CMV infection; a
phase III clinical trial comparing six weeks to six months of
valganciclovir therapy is actively enrolling infants. Preliminary
data from this trial reveal that GCV-resistant variants emerge
during therapy. Drug resistance also develops during prolonged or
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the problems associated with currently available anti-CMV
compounds, the very limited treatment options for congenital
CMV infection and the growing indications for CMV treatment,
we urgently need new anti-CMV compounds, especially com-
pounds with high oral bioavailability, low toxicity and low cost.
The antimalarial compound, sodium artesunate (Fig. 1, 2d), a
semisynthetic derivative of artemisinin (Fig. 1, 1), has good
tolerability, and lacks significant adverse side effects [16]. In
addition to its antimalarial activity, artesunate is cytotoxic to
several cancer cell lines [17]. Recently, artesunate was reported to
inhibit CMV replication in-vitro and in a rat CMV model,
exhibiting similar antiviral activity (same micromolar range) to
ganciclovir, while demonstrating no cytotoxicity [18,19]. The in-
vitro inhibition of clinical isolates ranged from 50–80% using
11.1 mM of artesunate [19]. The parent substance, artemisinin,
had lower anti-CMV activity compared to artesunate, suggesting
that different artemisinin derivatives may have variable effects on
CMV replication.
Dihydroartemisinin (Fig. 1, 2a, DHA), artemether (2c) and
artesunate (2d) were originally prepared in China in the 1970s.
These derivatives and others including artemisone, arteether and
artelinic acid are known as monomeric artemisinins. Artemisinin
dimers were later synthesized for use as a single dose therapy for
malaria in order to improve compliance. These orally active
compounds display potent antimalarial and anticancer activities
[20,21]. Other than artemisinin and artesunate, artemisinin
monomers and novel artemisinin dimers have not been tested as
potential anti-CMV compounds.
We evaluated the in-vitro anti-CMV activity of four artemisinin
monomers: artemisinin (1), artesunate (2d), artemether (2c), and
artefanilide (3) and two artemisinin dimers, each incorporating
two artemisinin units: dimer primary alcohol (4) and dimer sulfone
dimethyl carbamate (6). We show here that, based on the
concentration required for complete inhibition of CMV replica-
tion, artemisinin dimers have up to 500 fold higher activity against
CMV replication than the artemisinin monomers.
Materials and Methods
Ethics Statement
The clinical isolate, SB, was collected at the University of
Alabama at Birmingham, after obtaining local approval from the
office of Institutional Review Board and written informed consent.
The isolate was provided to Johns Hopkins with no identifiers that
can link to a specific subject. The Johns Hopkins School of
Medicine Office of Human Subject Research Institutional Review
Board (IRB-X) determined that the research qualified for an
exemption under 45 CFR 46.101(b).
Cells and viruses
Human Foreskin Fibroblasts (HFF) passage 12–16 and human
lung fibroblasts (HEL) passage 8–12 (from ATCC) were
maintained in DMEM containing 10% fetal bovine serum and
used for infections with the viruses. Cells in concentrations of
5610
4 and 1610
4 were seeded 24 hours prior to infection on each
well of 24-and 96-well plates respectively.
The CMV strains used for infections were the highly-passaged
Towne virus, and a clinical isolate obtained from the urine of a
neonate with congenital CMV infection (SB) and passaged once in
tissue culture. Experiments were performed with multiplicity of
infection (MOI) of 0.1, 0.5, 1, and 3. Initial experiments were
performed using a recombinant human CMV-green fluorescent
protein (GFP) virus, derived from Towne strain. This virus has a 9-
kb deletion from the dispensable unique short (US) region from
US1 to US12, and instead contains the bacterial artificial
chromosome sequences and a GFP expression cassette [22].
Based on pilot experiments using Towne-GFP we elected to use a
more sensitive luciferase reporter system to evaluate potential
differences in CMV inhibition by various artemisinin derivatives.
A recombinant virus expressing luciferase reporter gene under the
control of UL99 (pp28) late promoter was generated by insertion
of the reporter gene between the US9 and US10 ORFs in the
Towne genome. This extragenic reporter gene displays authentic
late transcription characteristics after infection of HFF [23]. Pp28
–luciferase expression is strongly activated at 48–72 hours and is
almost completely inhibited in the presence of DNA synthesis
inhibitors (GCV).
Compounds
Ganciclovir (GCV) was obtained from Roche, USA and stock
was prepared in aqueous solution. Artemisinin was obtained from
Sigma-Aldrich. Artesunate (1), artemether (2C), artefanilde (3),
dimer primary alcohol (4) and dimer sulfone dimethyl carbamate
(6) were synthesized at Johns Hopkins University (GHP) [24,25].
Stocks of artemisinin monomers and dimers were prepared in
dimethyl sulfoxide (DMSO) and stored in 220uC. Synthetic
compounds were at least 98% pure based on high performance
liquid chromatography. The DMSO itself was tested in CMV-
infected cells and it did not have any anti-viral activity. Fig. 1
depicts the monomers and dimers used in this study.
Antiviral assays
Towne-GFP, Towne–luciferase, and SB viruses were used in
these assays. HFF or HEL were grown to subconfluent monolayers
and infected with the CMV viruses at MOI 0.1 to 3. Based on
previously reported methods, cells were treated with artemisinin
derivatives at various concentrations and infected with CMV
30 min thereafter [19]. The concentration of each compound was
calculated and adjusted by volume such that it was constant
throughout the experiment. Following 90 minute incubation,
media was replaced with fresh media containing the drug used.
Infected and treated cells were incubated at 37uC in a 5% CO2
atmosphere for 3–10 days depending on the virus and the anti-
viral assay. The recombinant luciferase-expressing virus was
incubated for 72 hours, the GFP virus was incubated for 5 days,
and the clinical isolate for 10 days. All experiments were
subsequently repeated with compounds added to wells just after
viral inoculation.
For luciferase assay, WizardH SV Lysis Buffer (Promega,
Madison, WI) was added to each well, incubated for 10 minutes
at 37uC, followed by 10 minutes of freezing at 280uC and
incubation at 37uC for 10 minutes. Luciferase activity was
determined in cell extracts using an automated luminescent assay
(Promega, Madison, WI). The dynamic range of the luciferase
assay is 6–7 logs, and data obtained with it highly correlates with
real-time PCR and with plaque reduction assay (manuscript in
preparation). Cellular cytotoxicity was determined using CellTiter-
GloH Luminescent Cell Viability Assay (Promega, Madison, WI).
The assay determines the number of viable cells in culture based
on quantification of the ATP present.
For plaque reduction assay, human embryonic lung cells were
seeded into six-well plates and incubated at 37uC one day prior to
infection with the recombinant luciferase-expressing CMV. Serial
dilutions of GCV, artesunate and artefanilide were used. The virus
was diluted to a desired concentration which gave 50–60 plaques
per well. Medium was aspirated from the wells, and 0.2 ml of virus
suspension was added to each well in triplicates. Plates were
Artemisinins Inhibit CMV
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doi:10.1371/journal.pone.0010370.g001
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drugs were added and a methylcellulose overlay applied to each
well. After incubation for 10 days, cells were stained with crystal
violet. The stain was aspirated, wells were washed with phosphate-
buffered saline, and plaques were counted.
Western Blot for IE-1 and IE-2
Monoclonal antibodies to CMV immediate early proteins IE-1
and IE-2 (MAb810) and to cellular b-actin were purchased from
Millipore (Billerica, MA). Confluent cells were infected with CMV
in the presence of artemisinin compounds. At the indicated times
cells were harvested in sample buffer (RIPA buffer, Tris 50 mM,
Nacl 150 mM, SDS 0.1%, Na Deoxycholate 0.5%, NP40 1%, and
protease inhibitor cocktail), boiled and loaded onto SDS-PAGE.
Proteins were separated by electrophoresis and transferred to
nitrocellulose membrane. After blocking, blots were probed with
primary antibody (1:3,000) overnight at 4uC in phosphate-buffered
saline, and Tween. After washing 3 times, blots were probed with
HRP-conjugated anti-mouse (Sigma), 1:5,000 for 1 hour at room
temperature. Blots were washed three times in phosphate-buffered
saline/Tween, and then developed by enhanced chemilumines-
cence according to manufacturer protocol.
CMV US17 real-time PCR assay
To determine the inhibitory effects of artemisinins on DNA
copy number of SB clinical CMV isolate, we performed real-time
PCR. DNA was isolated from infected cells 10 days post infection
using WizardH SV Genomic DNA Purification System (Promega,
Madison, WI). The real-time PCR is based on detection of the
highly conserved US17 gene [26]. The primers and probe for
US17 are: forward- 59 GCGTGCTTTTTAGCCTCTGCA-39,
reverse 59- AAAAGTTTGTGCCCCAACGGTA-39 and US17
probe FAM- 59 TGATCGGGCGTTATCGCGTTCT-39. The
limit of detection is 10 copies/reaction (100 copies/mL) and the
dynamic range of the assay is 2.4–8.0 log10copies/mL.
Results
Pretreatment of human foreskin fibroblasts (HFF) with different
concentrations of artemisinin (1) followed by infection with GFP-
tagged CMV resulted in dose-dependent reduction in CMV
replication (data not shown). To better quantify the extent of
reduction and to compare the degree of CMV inhibition by
different artemisinin derivatives all subsequent experiments of
CMV inhibition were performed using the highly sensitive
luciferase assay and the pp28- luciferase expressing CMV.
The four monomers, artemisinin, artesunate, artemether and
artefanilide (Fig. 1), were tested first for CMV inhibition in
comparison with GCV. These monomers exhibited a similar
degree of anti-CMV activity. At 10 mM, ganciclovir (GCV) was
more potent in CMV inhibition than all four monomers (Fig. 2).
Similar results were obtained by a plaque reduction assay
performed in human embryonic lung cells (HEL) with the same
luciferase virus; at 10 mM, monomers achieved 40–50% reduction
in plaque formation, while GCV reached 80% reduction in plaque
formation.
We next evaluated CMV inhibition by the four monomers and
two dimers. Artemisinin dimers (Fig. 1- 4 and 6) were significantly
more efficient than the monomers in inhibition of pp28-driven
luciferase activity (Fig. 3, P,0.0001) without associated cellular
cytotoxicity (Table 1). The dimers were up to 500 fold more potent
than monomers in achieving complete inhibition of CMV
replication. Data presented in the figures was obtained from
CMV infected HFF. The same phenomenon of CMV inhibition
with dimers compared to monomers was also observed in HEL
cells. Error bars presented in figures 2 and 3 represent the
standard deviation of 6 experiments, each with three replicates.
Normalized luciferase activity is shown as the ratio of lumines-
cence units measured in drug treated CMV-infected cells vs. non-
treated CMV-infected cells.
Dimer primary alcohol (4) and dimer sulfone carbamate (6)
were reproducibly associated with dramatic inhibition of CMV
replication using different batches and passages of HFF, and HEL
cells.
To confirm that dimers did not block the luciferase enzyme in
the recombinant virus, which could have resulted in low luciferase
values, whole cell extracts of CMV-infected cells were treated with
either dimer primary alcohol or DMSO only. Luciferase activity,
measured after 30 minutes of incubation, revealed that lumines-
cence was similar between the dimer-treated (83,20061,670 units)
and the DMSO-treated cells (86,30062,490), supporting that
dimers did not affect the luciferase enzyme itself, but rather
inhibited CMV replication.
We evaluated differences in anti-CMV activity between
artemisinin monomers and artemisinin dimers using a clinical
isolate, SB. Cells were treated with either artemisinin monomers
or dimers and DNA was extracted from cell extracts 10 days post
infection. Real-time PCR showed that DNA copy number
decreased 20–35 fold more with dimers as compared to monomers
at 10 mM, and 4 fold more as compared to GCV (Fig. 4).
We calculated the selectivity index (SI) of all artemisinin
derivatives and GCV based on the effective drug concentration
that results in 50% virus inhibition, EC50, and the drug
concentration that leads to 50% cellular cytotoxicity, CC50
(Table 1). SI was determined as the ratio between CC50 and
EC50. For EC50 and CC50 reported values represent the mean and
SD of data derived from at least five independent experiments
performed in triplicates. The concentrations of monomers used for
calculating EC50 were 1, 5, 10, 25, 50, and 100 mM. The
concentrations of dimers used for EC50 calculations were 1 nM,
10 nM, 100 nM, 250 nM, 1 mM and 10 mM. The curve fitting
toolbox, Matlab software (v7.5), Mathworks (Natick, MA) was used
to determine EC50 values using a four-parameter logistic regression.
Figure 2. Relative lucifersae activity in CMV-infected HFF
treated with four artemisinin monomers. Luciferase assay was
performed 72 hr after HFF were treated with compounds and infected
with the recombinant luciferase-expressing CMV. Values on Y axis
adjusted to 0–1 scale. Mean6SD values are presented.
doi:10.1371/journal.pone.0010370.g002
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monomers. The dimer sulfone carbamate (6) had the highest
selectivity, approximately 10 times more than GCV (Table 1).
To confirm that the difference in anti-CMV activity between
monomers and dimers was not a result of instability of the
monomers in tissue culture, we determined the anti-toxoplasmosis
activity of these compounds in the supernatants of CMV infected
cells at 3–5 days post infection. Monomers used in CMV-infected
cells proved to inhibit toxoplasmosis in concentrations that
correlated with previous reports (Table 2) [27].
The expression of CMV immediate early (IE) protein was tested
by western blot to determine whether artemisinins’ inhibition of
CMV replication occurs early in the virus life cycle. The
expression of immediate early 1 (IE1) and GFP in cell lysates
treated with artemisinin and infected with Towne-GFP was
Figure 3. Effect of artemisinin monomers and artemisinin dimers on luciferase expression in CMV-infected HFF. Luciferase assay was
performed 72 hr after HFF were treated with monomers or dimers and infected with luciferase-expressing CMV. Values on Y axis adjusted to 0–1
scale. Mean6SD values are presented.
doi:10.1371/journal.pone.0010370.g003
Table 1. EC50,C C 50 and selectivity index (SI) for monomers,
dimers and GCV.
Compound CC50 (mM) EC50 (mM)
Selectivity
index (SI)
Dimer sulfone carbamate (6)2 8 . 1 69.6 0.0660.00 5086173
Dimer primary alcohol (4)5 7 62.3 0.1560.02 380653
GCV 247633.4 5.660.2 4466.2
Artemisinin (1)7 2 . 4 615.7 16.864.0 4.361.4
Artesunate (2d)7 7 . 5 614.4 18.565.2 4.262.2
Artemether (2c)1 8 . 4 67.5 5.362.7 3.562.2
Artefanilide (3)4 4 . 9 63.4 8.162.2 5.561.6
doi:10.1371/journal.pone.0010370.t001
Figure 4. CMV copies/mL at 10 days post infection in the
presence of monomers and dimers. HFF were infected with SB
clinical isolate (MOI=1) and treated with artemisinin (1), artefanilide (3),
and two dimers (4, and 6). Ten days following infection DNA was
extracted from cells and real-time PCR performed.
doi:10.1371/journal.pone.0010370.g004
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able using MOI of 0.1 (Fig. 5a). Further evidence for the early
effect of artemisinins on IE1 protein expression was obtained with
the clinical isolate (SB, Fig. 5b). IE1 expression was significantly
reduced in CMV infected cells (MOI=1) treated with 1 mM dimer
primary alcohol at 24 and 48 hr, but was not affected by 10 mM
GCV. The inhibition of IE1 expression with dimer primary
alcohol was observed as early as 12 hours post infection (SB,
MOI=3), prior to onset of DNA replication [28].
To determine whether pretreatment with artemisinin mono-
mers or dimers was necessary to achieve CMV inhibition, all
experiments were repeated with infection followed by treatment.
HFF were infected with pp28-luciferase expressing CMV
(MOI=1). After 90 minute incubation, unadsorbed virus was
removed, and appropriate concentrations of artemisinin mono-
mers or dimers were added. The data obtained with these sets of
experiments revealed that pretreatment with the compounds is not
required for their anti-CMV activity, and that the exact same
degree of CMV inhibition is achieved even when the compounds
are added after viral adsorption (Fig. 6).
Discussion
We report here that artemisinin-derived dimers are potent
inhibitors of CMV replication in-vitro with no significant
cytotoxicity. CMV inhibition by dimers was up to 500 fold higher
as compared to the four artemisinin monomers tested- artemisinin,
artesunate, artemether and artefanilide. The results obtained were
comparable using several anti-viral assays and different viral
strains- a laboratory adapted strain (Towne) and a clinical isolate.
CMV is an important pathogen in solid organ transplantation
[29], in patients with AIDS [30], and when transmitted during
pregnancy from mother to fetus [5]. In addition to these well-
documented syndromes, CMV replication has been recently
reported in immunocompetent individuals requiring medical care
in intensive care units, and in patients with glioblastoma multi-
forme [7,9]. Thus, the target population for CMV therapeutics
may be growing.
Drugs currently licensed in the US to treat CMV target the viral
DNA polymerase and block elongation of the viral DNA chain.
They are highly effective in prevention and treatment of CMV
disease. However, toxicities, development of drug resistance and
Table 2. EC50 of monomers and dimer primary alcohol for
CMV and Toxoplasmosis.
Compound EC50 (mM) - CMV EC50 (mM) - Toxoplasmosis
Artemisinin 15.764.5 4.161.1
Artesunate 17.263.4 3.260.8
Artemether 5.162.1 0.5860.22
Dimer Primary Alcohol 0.1660.04 0.4060.15
doi:10.1371/journal.pone.0010370.t002
Figure 5. Western blot for IE1, GFP and b actin in artemisinin treated CMV infected cells. 5a: HFF were treated with artemisinin 0, 1 mM
and 100 mM and infected with GFP-tagged Towne. Western blot for IE1 and GFP performed at day 5 post infection. 5b: HFF were infected with a
clinical isolate, SB, and treated with either dimer primary alcohol (1 mM) or GCV (10 mM). Western blot for IE1 was performed at 12 hr (MOI=3), 24 hr
and 48 hr (MOI=1) post infection.
doi:10.1371/journal.pone.0010370.g005
Artemisinins Inhibit CMV
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limitations to their use. New anti-CMV drugs have been
developed to overcome these drawbacks. Maribavir, targeting
the UL97 kinase [31] is a potent inhibitor of laboratory and
clinical isolates of CMV [32]. Despite promising results of phase II
multicenter, randomized, double-blind, placebo-controlled study
[33], a recent multicenter phase III study in bone marrow
transplant recipients showed no statistically significant difference
between maribavir and placebo in reducing the rate of CMV
disease. In addition to compounds that directly inhibit viral
targets, there is a growing interest in compounds that may affect
host cell functions required for efficient virus replication [34].
Artesunate (2d), a semisynthetic derivative of artemisinin (1),
the active compound of the Chinese herb Artemisia annua, is highly
active against malaria parasites. It is available orally, has good
tolerability, and lacks significant side effects [16]. Artesunate was
first reported to inhibit CMV replication in-vitro similar to GCV
[19]. A subsequent study performed in a rat CMV model revealed
that the parent compound, artemisinin, had lower anti-CMV
activity compared to artesunate [18]. In the first report by Efferth
[19], artesunate was shown to inhibit several laboratory adapted
strains and clinical isolates with the most significant inhibition
observed in HEL cells infected with Towne virus. However, in
CMV infected HFF inhibition with artesunate was modest. The
effect of cell culture conditions on the activity of anti-CMV activity
has also been reported for maribavir [35], with more effective
suppression of viral growth observed in HEL (lung fibroblasts)
than in HFF (foreskin fibroblasts). Our data reveal that in both
HFF and HEL cells dimers were significantly more effective in
CMV inhibition than monomers.
Artemisinin dimers were originally synthesized to provide a
single dose regimen for malaria. Although the first generation of
dimers was unstable, the second-generation proved to be thermally
and hydrolytically stable [36]. These orally active compounds
display potent antimalarial and anticancer activities [20], but they
do not have an advantage over artemisinin monomers in clearing
malaria parasites as observed in CMV inhibition. Multiple
mechanisms may contribute to the anti-cancer activities of
artemisinins [37], including inhibition of cell proliferation,
induction of G0/G1 cell cycle arrest and promotion of apoptosis
[21]. New dimeric sulfones were reported to cure malaria infected
mice with a single oral dose and to be selectively and powerfully
cytotoxic to cancer cells [25]. The concentrations effective in
cancer cells are similar to those that inhibit CMV replication.
In CMV infected cells it appears that dimers do have an
enhanced CMV inhibition over monomers. These inhibitory
effects appear early during virus replication cycle as evidenced by
decreased expression of CMV IE1 protein, in agreement with
prior work [19]. Decreased expression of IE1 will prevent all
subsequent steps in the virus replication cycle as shown by
decreased DNA synthesis (by real-time PCR) and decreased
expression of late CMV proteins (pp28-luciferase assay).
A suggested mechanism of action of artesunate in CMV infection
is the inhibition of cellular pathways that play an essential role in
viral replication [38]. In artesunate-treated infected cells, Sp1 and
NF-kB as well as cellular signaling kinase phosphoinositide 3-kinase
(PI3K), required for the activation of Sp1 and NF-kB, were
markedly reduced [19]. Although at this time the mechanism of
CMV inhibition is largely unknown, better understanding of it will
have important clinical implications. Our data suggest that
inhibition of CMV replication does not occur at the time of binding
of CMV to the cellular receptors, because the compounds are
effective even after infection. The fact that dimers are significantly
more potent than monomers may suggest improved binding to their
specific target than the monomers. Mechanistic studies are ongoing
and will be reported in the near future.
In summary, we show here for the first time that artemisinin
dimers are dramatically more inhibitory to CMV replication then
artemisinin monomers, without associated cytotoxicity. Dimers,
although containing only two artemisinin units, are shown here to
be much more than twice potent as anti-CMV agents than the
corresponding monomeric artemisinins. The anti-viral activity was
observed with a laboratory adapted strain and a clinical isolate of
CMV. Future work will examine which dimer has the most potent
anti-CMV activity and best selectivity index. In addition, other cell
types should be tested to confirm the anti-CMV effects of
artemisinin monomers and artemisinin dimers. Although experi-
ence in humans with artemisinins in CMV disease is not available
yet,artesunatewassuccessfullyused totreatachildwith ganciclovir-
resistant CMV following bone marrow transplantation [39].
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